Diagnos Inc. Market Research Report
Company Overview
Name, Mission
Diagnos Inc.
- Mission: To develop AI tools to assist healthcare professionals in the detection of critical health issues.
- Tagline: "Where AI Becomes Real."
Founding and Founder
- Founded: 2001
- Founder: No information is available
Key People
- President: André Larente
- CEO: André Larente
- CFO: Marc-André Massue
- VP Sales, Latin America: Guillermo Moreno Robles
- COO: Yves-Stéphane Couture
- VP Business Intelligence: Riadh Kobbi
Headquarters
- Location: 7005 Taschereau Boulevard, suite 265, Brossard, QC J4Z 1A7, Canada
Number of Employees
- No information is available
Revenue
- No information is available
Notability
Diagnos Inc. is known for its leadership in artificial intelligence (AI) and healthcare technical services including:
- Algorithm Development
- Data Analysis
- Image Processing
Products
Overview
Diagnos offers AI-driven healthcare technology solutions with a focus on preventing vision loss and other detrimental consequences of chronic diseases.
Key Products
CARA (Computer Assisted Retina Analysis)
- Description: A platform designed for importing, processing, and storing both original and enhanced retinal images through computerized networks.
- Key Features:
- Image Processing: Assists in detecting diabetic retinopathy and other eye diseases.
- Algorithm Development: Enhances the detection of critical health issues.
- Data Mining/Artificial Intelligence: Provides predictive analytics for better decision-making.
Recent Developments
New Products and Features
New Product Launches
- CARA-STROKE: Application for early detection and prevention of stroke (Clinical trial in the USA starting Dec 6th, 2021).
New Features Added to Existing Products
- Age-Related Macular Degeneration Detection Application integrated into optometry clinics of IRIS, The Visual Group (Announced Jun 7th, 2022).
- New Analysis Modules in development stages related to Health Canada and US FDA applications.
New Partnerships
- EssilorLuxottica: Exclusive distribution agreement for Canada (Announced Dec 11th, 2023).
- Labtician Ophthalmics: Renewed distribution agreement; launched new screening service for diabetic retinopathy in Ontario (Announced May 21st, 2024).
- Juarez Health & Medical Tourism Cluster: Multi-year contract (Announced Sep 16th, 2021).
- Optina Diagnostics: Three-year contract renewal providing a telemedicine platform (Announced Sep 2nd, 2021).
- Novo Nordisk: Contract extension for patient follow-ups under treatment with their drug portfolio (Announced Apr 26th, 2022).
Regulatory and Certification Achievements
- ISO 13485 / MDSAP Certification: Enhanced compliance with medical device regulations (Announced Aug 20th, 2024).
- FDA and Health Canada Compliance: Certifications for new analysis modules (In process as of Apr 16th, 2024).
Financial Developments
- Private Placement Closings:
- Feb 27th, 2024
- Mar 22nd, 2024
- Sep 20th, 2024
Market Recognition
- Top TSX Venture Exchange Company: Recognized on Feb 21st, 2024.
Board Appointments
- Dr. Philippe Couillard: Joined Board of Directors (Announced Apr 2nd, 2024).
- Michael Braeuel: Joined Board of Directors (Announced Feb 29th, 2024).
Contacts
- Address: 7005 Taschereau Boulevard, suite 265, Brossard, QC J4Z 1A7, Canada
- Phone: +1 (450) 678-8882
- Email: info@diagnos.com
For further details, visit the [Diagnos Inc. Website](http://www.diagnos.com).
This market research report is created based on publicly available information and press releases for Diagnos Inc.
